Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis: Erratum
No abstract available (Source: Melanoma Research)
Source: Melanoma Research - November 9, 2022 Category: Cancer & Oncology Tags: Erratum Source Type: research
Adrenal metastatic melanoma first identified during pregnancy: a diagnostic challenge
Adrenal nonadenomatous tumors (NAT) first identified during pregnancy are very rare and pose a diagnostic and therapeutic dilemma with significant risks for the mother and fetus. The aim of this study is to report a case of a large adrenal NAT identified in pregnancy and literature review. A literature search was conducted, and data were summarized. A 37-year-old primigravida woman, with a history of melanoma, excised 12 years before presentation without recurrence, presented at 35 weeks gestation due to intractable right flank pain. MRI demonstrated an eight cm, heterogeneous, septate, right adrenal mass suspected to ...
Source: Melanoma Research - November 9, 2022 Category: Cancer & Oncology Tags: Short Communications: Clinical Research Source Type: research
Successful use of rituximab for refractory hemophagocytic lymphohistiocytosis in a melanoma patient treated with targeted therapy
We report a 64-year-old man, with advanced BRAF-mutant melanoma treated by combined targeted therapies who had a recalcitrant and cortico-dependent Epstein–Barr virus (EBV)-induced HLH. One rituximab cycle led to a rapid and prolonged HLH remission which allowed to switch the targeted therapy for immunotherapy rituximab thus makes it possible to limit the use of corticosteroids, which limits the effectiveness of immunotherapy. The patient finally died of a cerebral tumoral progression 2 years later. Despite secondary hypogammaglobulinemia, we did not observe any severe infections during this period. This case suggests ...
Source: Melanoma Research - November 9, 2022 Category: Cancer & Oncology Tags: Short Communications: Clinical Research Source Type: research
Clinical characteristics and treatment outcomes of non-V600 E/K BRAF mutant melanoma patients: a single-institution experience
The widespread use of more sensitive detection tools, such as next-generation sequencing, has increased the identification of a variety of BRAF mutations other than V600E/K in melanoma patients. However, there is a lack of established data regarding the efficacy of BRAF/MEK inhibitors and immune-checkpoint immune inhibitors (ICI) for these patients. We performed a retrospective study, including all the patients diagnosed with stage III or IV melanoma that were referred to the University Hospital of Bologna from 2011 to 2021, carrying a non-V600E or V600K mutation of BRAF and who were started on systemic treatment. We found...
Source: Melanoma Research - November 9, 2022 Category: Cancer & Oncology Tags: Original Articles: Clinical Research Source Type: research
The importance of mitosis ≥2 in selecting patients with T1 cutaneous melanomas for sentinel lymph node biopsy
This study investigates whether MR plays a role in selecting patients with T1 melanoma for SLNB. We analyzed clinical and histological data from the Florence Melanoma & Skin Cancer Unit database for 313 patients with a single thin melanoma who had undergone SLNB. We determined sentinel lymph node (SLN) positivity percentages in T1 melanomas according to the AJCC 8th Edition focusing on MR. Of the 313 T1 patients, 108 had MR = 0, 127 had MR = 1 and 78 had MR ≥2. The overall SLN positivity rate was 8.6%, (5.6% with MR = 0, 6.3% with MR = 1 and 16.7% with MR ≥2). The SLNB positivity rate in T1b melanomas w...
Source: Melanoma Research - November 9, 2022 Category: Cancer & Oncology Tags: Original Articles: Clinical Research Source Type: research
Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors
This study aimed to investigate these patients’ real-world survival and identify the characteristics of long-term survivors. (Source: Melanoma Research)
Source: Melanoma Research - November 9, 2022 Category: Cancer & Oncology Tags: Original Articles: Clinical Research Source Type: research
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series
Anti-programmed cell death protein 1 (PD1) antibodies, pembrolizumab and nivolumab, alone or in combination with ipilimumab, have become standard treatment for melanoma and multiple other malignancies. Neurological adverse effects are rare and have not been well characterized to date. (Source: Melanoma Research)
Source: Melanoma Research - November 9, 2022 Category: Cancer & Oncology Tags: Original Articles: Clinical Research Source Type: research
CD103 and periplakin are potential biomarkers for response of metastatic melanoma to pembrolizumab
This study was designed to screen for preliminary evidence of predictive markers of melanoma response to PD-1 blockade. We hypothesized that the following immune markers would be positive predictors of response: increased densities of CD103+CD8+ T cells or Th1 lineage T-bet+ T cells, high expression of CXCL9-11 and presence of tertiary lymphoid structures. Conversely, we hypothesized that the high expression of barrier molecules would be a negative predictor of response. Patients with advanced melanoma treated with pembrolizumab were identified, and clinical response as well as overall survival data were collected. Tumor s...
Source: Melanoma Research - November 9, 2022 Category: Cancer & Oncology Tags: Original Articles: Translational Research Source Type: research
Melanoma cell plasticity poses diagnostic challenges: a case series
Phenotype switching is an emerging concept in melanoma research and deals with the cancer cell plasticity. In this paper, we present five cases of patients with metastatic malignant melanoma where the tumor underwent dramatic morphological and immunohistochemical changes thereby mimicking other types of malignancies. The diagnosis of melanoma in all these cases was based on the mutational profile of the tumor assessed by next-generation sequencing compared to the primary lesion or local regional lymph nodes. These cases highlight the importance of thorough diagnostic measures in patients with metastatic melanoma who show p...
Source: Melanoma Research - November 9, 2022 Category: Cancer & Oncology Tags: Original Articles: Translational Research Source Type: research
LS-007 inhibits melanoma growth via inducing apoptosis and cell cycle arrest and regulating macrophage polarization
This study aimed to investigate the role of LS-007 in B16F10 melanoma and relevant mechanisms. LS-007 significantly inhibited viability and induced apoptosis of B16F10 cells in a dose-dependent manner, which were accompanied with the increased ratio of Bax to Bcl-2 and decreased Mcl-1 mRNA level. Western blot analysis showed that LS-007 increased the expression of cleaved caspase-3 and poly ADP-ribose polymerase (PARP). Furthermore, flow cytometry analysis and qRT-PCR results showed that LS-007 treatment resulted in cell cycle arrest by changing cell cycle-related gene expression. Notably, in vivo evaluation showed that LS...
Source: Melanoma Research - November 9, 2022 Category: Cancer & Oncology Tags: Original Articles: Basic Research Source Type: research
Melanoma risk during immunomodulating treatment
Immunosuppressive therapy is standard for the treatment of inflammatory diseases and for minimizing rejection in transplant patients. However, immunosuppressant drugs are associated with an increased risk of certain cancers. In particular, melanoma is an immunogenic tumor and as such, is strongly influenced by the immune system. We performed this literature review to summarize the effects of commonly used immunomodulating agents on melanoma development, recurrence and progression. We outline the mechanism of action of each drug and discuss the available evidence on its influence on melanoma. Based on existing literature, w...
Source: Melanoma Research - November 9, 2022 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Ultraviolet A radiation exposure and melanoma: a review
The incidence of cutaneous melanoma has been increasing worldwide, and melanoma disproportionately contributes to skin cancer mortality. The pathogenesis of melanoma involves genetic and environmental factors, and while the effects of ultraviolet B radiation on melanoma development are well researched, fewer studies have investigated the role of ultraviolet A (UVA) radiation. We comprehensively reviewed cell, animal and epidemiology studies on the association between UVA exposure and melanomagenesis. UVA radiation has been found to have negative effects on melanocytes due to the induction of oxidative stress, dysregulation...
Source: Melanoma Research - November 9, 2022 Category: Cancer & Oncology Tags: Review Articles Source Type: research
Resistance to anti-PD1 therapies in patients with advanced melanoma: systematic literature review and application of the Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce anti-PD1 resistance definitions
Nearly half of advanced melanoma patients do not achieve a clinical response with anti-programmed cell death 1 protein (PD1) therapy (i.e. primary resistance) or initially achieve a clinical response but eventually progress during or following further treatment (i.e. secondary resistance). A consensus definition for tumor resistance to anti-PD1 monotherapy was published by Society for Immunotherapy of Cancer Immunotherapy Resistance Taskforce (SITC) in 2020. A systematic literature review (SLR) of clinical trials and observational studies was conducted to characterize the proportions of advanced melanoma patients who have ...
Source: Melanoma Research - November 9, 2022 Category: Cancer & Oncology Tags: Review Articles Source Type: research
BRCA1-associated protein 1 c.368delG mutation leads to the development of multiple BAPomas and cutaneous melanomas: a novel pathogenic variant in BRCA1-associated protein tumor predisposition syndrome
No abstract available (Source: Melanoma Research)
Source: Melanoma Research - September 10, 2022 Category: Cancer & Oncology Tags: Letters to the Editor Source Type: research
Challenging pigmented lesions in melanoma patients during checkpoint-inhibitors therapy
No abstract available (Source: Melanoma Research)
Source: Melanoma Research - September 10, 2022 Category: Cancer & Oncology Tags: Letters to the Editor Source Type: research
